This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Riedel, W. J. Articles by Schmitt, J. A. J. Search for Related Content PubMed PubMed Citation Articles by Riedel, W. J. Articles by Schmitt, J. A. J. Social Bookmarking                         What's this?

Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment

Experimental Psychopharmacology Unit, Brain and Behaviour Institute, Faculty of Psychology, Universiteit Maastricht, The Netherlands, w.riedel{at}psychology.unimaas.nl

Karin Eikmans

Experimental Psychopharmacology Unit, Brain and Behaviour Institute, Faculty of Psychology, Universiteit Maastricht, The Netherlands

Annet Heldens

Experimental Psychopharmacology Unit, Brain and Behaviour Institute, Faculty of Psychology, Universiteit Maastricht, The Netherlands

Jeroen A. J. Schmitt

Nutrition and Health Department, Nestle Research Center, Lausanne, Switzerland

Subchronic treatment with the selective serotonergic reuptake inhibitors (SSRIs) fluoxetine, venlafaxine and paroxetine, but not sertraline, were previously shown to specifically impair vigilance performance. The current study was designed to compare the vigilance effects of subchronic treatment with the SSRIs sertraline and citalopram in healthy volunteers, according to a placebo-controlled, double-blind, three-way cross-over design. Twenty-four healthy subjects, aged 30-50 years, of whom 21 completed the study, underwent three treatment periods of 2 weeks in which they received sertraline (50 mg on days 1-8, 100 mg on days 8-15), citalopram (20 mg on days 1-8, 40 mg on days 8-15) and placebo. Treatment periods were separated by 14 days washout periods. Vigilance performance was assessed through a 45-min Mackworth Clock Test at days 1, 8 and 15 of each treatment period. It was found that citalopram impaired vigilance performance acutely after the first 20 mg dose and subchronically after 40 mg daily doses. By contrast, no vigilance impairment was found during sertraline treatment. Sertraline is the only SSRI studied so far with no detrimental effects on vigilance. This may be due to the affinity of sertraline for the dopamine reuptake site. Because citalopram is the most specific SSRI showing this effect, it is concluded that the SSRI-induced decrement of vigilance performance is specifically associated with serotonergic reuptake inhibition.

Key Words: citalopram • cognitive function • serotonin-drug-effects • sertraline • SSRIs • vigilance

Journal of Psychopharmacology, Vol. 19, No. 1, 12-20 (2005)
DOI: 10.1177/0269881105048887


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Hasler, E. Studerus, K. Lindner, S. Ludewig, and F. Vollenweider Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA J Psychopharmacol, November 1, 2009; 23(8): 923 - 935. [Abstract] [PDF]

				M. Wingen, K.P.C. Kuypers, and J.G. Ramaekers Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI J Psychopharmacol, July 1, 2007; 21(5): 477 - 485. [Abstract] [PDF]